To achieve the goal of adding new companies and products, we need to focus more on translational research and early-stage companies in digital health, diagnostics, and therapeutics still in ideation. There needs to be fundamental changes on how to approach the new solutions and that requires us to rethink how technology and life sciences are utilized for NDD.